Better choice - Better lifeVivamart is bringing new exotic products to all its market segment and improving lives using its unique logistics solutions. Buy a bigger variety of products at www.vivamart.no and save time while ordering as well as recieving all products at home. By saving multiple long distance shopping trips, we help to reduce CO2 emissions.

Rada Labs are bringing app ideas to life. With a big focus on creativity and innovation the company develop never seen before applications for smartphones, tablets, smart watches and computers. Rada Labs consists of creative people who love to develop high quality products and services. With innovation in focus, we develop our own brands within apps as well as develop applications for our customers. We build apps for smartphones, smartwatches, tablets and computers. By using tailored innovation processes and the latest technology in cloud services, machine learning and artificial intelligence, we can create smart applications that reach all target groups!

UNISOT is a young Norwegian start-up company and is the first global Blockchain solution based on tight integration with Enterprise Resource Planning (ERP) systems, such as SAP and other major ERP and SCM systems. Its permissionless manner will allow unprecedented abilities for secure information exchange and secure information storage to companies and/or organizations all over the world. For the first time and with the help of the open, public blockchain, UNISOT can now offer access to a reliable and secure “Universal Source of Truth” that all parties can use to handle the challenges in today’s supply chain environment, such as increased globalization, faster pace of change, global traceability, information shortage, and settlement costs, to name a few. UNISOT is leveraging the very well-established ERP Business Processes with the trust, security, immutability, and tokenization that the Open Public Permissionless Blockchain technology provides.

Nyoppstarta informasjon og IT-sikkerhetsfirma i Tønsberg. Gir rådgivning innen sikker bruk av IKT i små og mellomstore bedrifter. Disse bedriftene kan være sårbare med få ansatte og spesialisert ekspertise innen sine fagområder. GuardIT gir veiledning i bruk av digitale hjelpemidler, vurdering av systemsikkerhet og daglige rutiner. Ta kontakt på post@guardit.no for mer informasjon.

Renteradar monitors our users' mortgage rates over time and compares them to the offers available in the market. We want to make the process of monitoring and comparing mortgage rates as easy as possible by creating transparency. We automatically match our users with their cheapest lenders as well as assist in the following transition. Our system uses BankID to collect the required information which makes the experience as effortless and uncomplicated as possible.

HØYDENDesignet i Bergen. Visjonen for klokkene har vært å oppnå et uttrykk langt utover det som er vanlig i dette prissegmentet. Høy kvalitet og utmerket finish, bygget med 100% sveitsisk urverk. Designet og utviklet av grunnlegger Kristian Høyden i Bergen, Norge.Krystallglass, 5ATM (vann), 316 Stainless Steel. Ronda urverk fra Sveits. (For ytterligere detaljer, vennligst besøk www.hoydentimepieces.no).

Det er stor konkurranse om de beste hodene i Norge, og det strekker desverre ikke til for alle de fantastiske idèene og bedriftene vi har.Outsourcing er sjeldent en god løsning da det bringer høy kompleksitet, lav utviklingshastighet og store sjanser for kommunikasjonsproblemer. Behovet for A-lags-spillere er høyt.Homesourcing finner fantastiske personer i Europa og integrerer de i norske utviklingsteam. Vi mener det finnes mer enn nok av utviklere i verden, men for få utviklere som også har lederevner. Vi coacher og bygger utviklere til ledere for å sørge for de blir like effektive som oss nordmenn og kan ta et større ansvar. Ikke minst kunne tenke selv og ta gode avgjørelser for teamene de er i.

We make smart collection systems for the circular economy. Helping companies get their circular products back from consumers. So that the products can be reused, refurbished or recycled. Think reverse vending machines for bottles and cans- but for other products, and with a twist of cutting edge technology and beautiful design. We’re an early phase start-up based in Oslo, collaborating with some of the largest companies in the world, helping them transition from linear to circular. We are located at StartupLab at Oslo Science Park, the epicentre of Norway’s tech start-up scene. As part of the GRIN team, you will be given the opportunity to shape and scale a company, as well as innovating, developing, and growing new global business models necessary for a sustainable future.

ExperWELL AS was established in 2016 by an innovative group of Ph.D. scientists and engineering professionals in resin technology and services for the oil and gas industry. Our focus is to be reliable, competent, innovative, and flexible. Our head office is in Norway. ExperWELL® today has different partners and agents in different countries. Our vision is to be the world leader in resin products & services for downhole applications in the oil and gas industry. Our mission is to provide eternal good barriers from innovating, environment-friendly resin. ExperWELL®’s strength lies in its experienced Ph.D. scientists who have many years of experience in resin product development and realization, as well as its experienced professional engineers in an understanding of oil & gas reservoir description and flow dynamics leading to individual well and field production performance. We are proud of what we do and strive for success with our passionate team of dedicated people. ExperWELL®’s Top Management Team always knows that the highest importance is the environment as well as the Health and Safety of our staff, persons working with our products and on our behalf, and anyone else who may be related to our operations. That is why our product development and realization is focused on GREEN and environment-friendly products which eliminate adverse effects on the environment and personnel. The Company aims to develop our proprietary main products which are safe to use as household goods.

GI ALLE MULIGHET TIL Å INVESTERE I VEKSTSELSKAPER GJENNOM AKSJEKJØP. Folkeinvest AS ønsker med webtjenesten folkeinvest.no å demokratisere investering i oppstartsselskaper.Emisjonsprosessen har frem til nå være komplisert både for selskapet og de som vil investere. Derfor har slike investeringer vanligvis kun blitt tilbudt bekjente av selskapet og profesjonelle investorer.Folkefinansiering med lave minstebeløp og en lettfattelig webtjeneste gir alle mulighet til å investere.Å investere i oppstartsselskaper er forbundet med risiko for at investeringen kan gå tapt. Mange selskaper overlever ikke sine fem første år. Men det er også i den fasen at verdistigningen kan bli høy. Vi mener at denne investeringsmuligheten bør være tilgjengelig for alle.Folkeinvest.no har åpne investorlister, diskusjonsforum og krav til dokumentasjon som gjør at aksjekjøpere er godt rustet til å ta investeringsbesluttninger.

UpStacked is the All-in-One centralized operations platform that crushes SLA requirements to increase profitability and reduce OPEX. Purpose-built for internal IT and MSPs to operate SMBs and Enterprises. With user experience in mind, UpStacked drives complex to zero-touch, through automation and machine learning. UpStacked at a Glance: - All-in-One Centralized Platform - Enterprise onboarding in minutes - Third-Party integrations - Zero-Touch - Simplified License Management - Real-Time On-Demand Reporting - Real-Time Topology Based Correlation - Real-Time Event-Based Correlation - Built-in Role Based Access Control - Natively Multi-Tenant - Multi-Vendor - ITIL

Movel AS provides support and invoicing services for AC charging systems. We specialize in systems that provide normal charging for long-term and overnight parking. Movel wants to contribute to a more environmentally friendly life. Therefore, all power in Movel's charging systems provides renewable energy.

Biozep is discovering and developing first-in-class drug products for the treatment of severe eye diseases which can lead to vision loss and where it is a high unmet medical need. Biozep has discovered novel drug substances based on bioactive lipids which modulate central pathways involved in the pathogenesis of eye diseases. Targets and biomarkers are identified based on a system biology approach combined with in-depth knowledge about bioactive lipids, their endogenous synthesis and mechanisms of action. Biozep has made a prototype drug product based on our lead compound for topical administration and the product will be tested in animal models in 2018. Our goal is to start clinical studies in 2020. Biozep is a company depending on both internal and external resources. Biozep has established its own laboratory in Oslo in order to do synthesis, purification, quality control and chemical development in-house. The biological testing of the drug substances is performed in collaboration with carefully selected contract research organizations both in Europe and the USA. In order to reach the market as fast as possible and to reduce risk, Biozep will seek strategic partnerships early in the drug development phase. Biozep seeks partners with complementary competence and with resources to conduct clinical trials and with market access. We are already in dialogue with potential partners and hope to sign an agreement in 2018-19.

RESPINOR is a privately-owned medical device company, founded in Oslo, 2015. We have developed an objective measure of breathing for critically ill patients within intensive care. The technology provides precise, continuous and real-time information of diaphragm function, our main breathing muscle, to increase the quality of care and reducing costs. RESPINOR’s technology is the winner of Horizon 2020 both in phase I and II. We are addressing an unmet medical need because every breath counts.

New drugs for treating diseases of Down syndrome. More than 1% of the global GDP is spent on nursing demented people, and the number requiring nursing will triple within 2050. The disease is progressive, leading to death. There is no current cure available, only symptomatic treatments. Individuals born with Down syndrome have a more than 10x risk of developing dementia as well as a host of other diseases including diabetes. Our drug target, DYRK1A is an enzyme found on chromosome 21, and is considered a key factor determining developmental and medical challenges faced by individuals with Down. The enzyme interacts with multiple biological mechanisms involved in Alzheimer’s and autoimmune diseases. Advanced drug designUsing advanced drug design technologies, we have designed a potent DYRK1A inhibitor drug, PST-900. A use and substance of matter patent have been applied for. The company is currently working on chemical Lead Optimisation with 8 full-time medicinal chemists contracted.Financing and milestonesThe Company raised NOK 5 million in 2015 and 8.8 MNOK in 2016/2017, matching non-dilutive research (BIA) and business grants (Innovation Norway). We demonstrated Proof of Principle in a model system for Alzheimer’s disease in 2Q2016. We have also demonstrated that our drug is capable of reversing diabetes in an animal model. Together with clinical and regulatory advisors, we have identified an important unmet need for a drug to treat newly diagnosed diabetes. We will use this indication to quickly progress to market and from there develop analogous drug molecules in Alzheimer’s disease, focused especially in Down syndrome. Funding soughtThe current funding round will raise 15+ MNOK to fund the progression to the final Development Candidate during 2018. Following this, further funding will be sought to perform toxicology/safety and Phase 1 clinical studies. A highly experienced teamThe team behind Pharmasum Therapeutics have broad, international pharmaceutical and biotechnology experience, and is supported by an excellent group of advisors. Anders Fugelli, Ph.D., CEO. John Sigurd Svendsen, Ph.D., CSO. Pauline Stewart-Long, Ph.D. Project Management. Henning Mork, CFO. Board of Directors: Andrew Parsons, PhD. Øystein Soug, MSc. Mark Treherne, PhD, John Sigurd Svendsen, PhD.